Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-8068 + adebrelimab + HS-10516
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
SHR-8068 + adebrelimab + HS-10516 is an investigational combination therapy being developed by Suzhou Suncadia Biopharmaceuticals (a subsidiary of Jiangsu Hengrui Pharmaceuticals) for the treatment of advanced renal cell carcinoma (RCC). This triplet regimen combines two immune checkpoint inhibitors—SHR-8068, a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and adebrelimab (SHR-1316), a monoclonal antibody targeting programmed death-ligand 1 (PD-L1)—with HS-10516 (also known as HRS-10516), a novel small-molecule tyrosine kinase inhibitor (TKI) that primarily targets vascular endothelial growth factor receptors (VEGFR). By simultaneously inhibiting the PD-L1 and CTLA-4 pathways to restore T-cell activity and utilizing a TKI to inhibit angiogenesis and tumor proliferation, the combination aims to provide synergistic anti-tumor efficacy in patients with advanced or metastatic RCC.
- Other names
- SHR-8068 + adebrelimab + HS-10516SHR-8068 + adebrelimab + HRS-10516
02
Targets
EPAS1 (Hypoxia-inducible factor 2-alpha)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on SHR-8068 + adebrelimab + HS-10516.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-8068 + adebrelimab + HS-10516.